Opaleye Management as of June 30, 2026
Portfolio Holdings for Opaleye Management
Opaleye Management holds 58 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 17.7 | $195M | 2.4M | 79.73 | |
| Eton Pharmaceuticals (ETON) | 9.4 | $104M | 2.9M | 36.20 | |
| Harrow Health (HROW) | 9.2 | $102M | 2.4M | 42.47 | |
| Disc Medicine (IRON) | 5.7 | $63M | 855k | 73.14 | |
| Urogen Pharma (URGN) | 4.8 | $53M | 1.4M | 36.80 | |
| Apogee Therapeutics (APGE) | 4.7 | $52M | 390k | 132.73 | |
| Meiragtx Holdings (MGTX) | 4.3 | $48M | 3.6M | 13.51 | |
| Sol-gel Technologies Shs New (SLGL) | 3.4 | $37M | 500k | 74.14 | |
| Rezolute Com New (RZLT) | 3.0 | $33M | 6.3M | 5.20 | |
| Tg Therapeutics (TGTX) | 2.7 | $29M | 535k | 54.94 | |
| Immix Biopharma (IMMX) | 2.2 | $24M | 2.3M | 10.31 | |
| Crescent Biopharma (CBIO) | 2.2 | $24M | 1.3M | 18.00 | |
| Stoke Therapeutics (STOK) | 2.1 | $23M | 700k | 32.72 | |
| Alpha Cognition Com New (ACOG) | 1.9 | $21M | 2.9M | 7.22 | |
| Edgewise Therapeutics (EWTX) | 1.8 | $20M | 500k | 40.63 | |
| Revolution Medicines (RVMD) | 1.7 | $19M | 100k | 187.28 | |
| Monte Rosa Therapeutics (GLUE) | 1.6 | $18M | 745k | 24.20 | |
| Alumis (ALMS) | 1.4 | $16M | 550k | 28.14 | |
| Codexis (CDXS) | 1.4 | $15M | 6.8M | 2.26 | |
| Replimune Group (REPL) | 1.4 | $15M | 1.4M | 11.07 | |
| Xoma Royalty Corporation Com New (XOMA) | 1.3 | $14M | 338k | 42.50 | |
| Mbx Biosciences (MBX) | 1.3 | $14M | 260k | 55.20 | |
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $14M | 123k | 111.03 | |
| Editas Medicine (EDIT) | 1.1 | $13M | 3.9M | 3.24 | |
| Protagonist Therapeutics (PTGX) | 1.1 | $12M | 100k | 122.58 | |
| Cabaletta Bio (CABA) | 1.1 | $12M | 3.9M | 3.11 | |
| Q32 Bio (QTTB) | 1.1 | $12M | 931k | 12.74 | |
| Annexon (ANNX) | 0.9 | $9.8M | 1.7M | 5.71 | |
| Verastem Com New (VSTM) | 0.6 | $6.9M | 1.8M | 3.82 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.6 | $6.9M | 1.4M | 4.85 | |
| Relmada Therapeutics (RLMD) | 0.6 | $6.5M | 935k | 6.92 | |
| Ocular Therapeutix (OCUL) | 0.5 | $5.9M | 600k | 9.82 | |
| Trevi Therapeutics (TRVI) | 0.5 | $5.8M | 310k | 18.65 | |
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.5 | $5.3M | 700k | 7.62 | |
| Lyell Immunopharma Com New (LYEL) | 0.4 | $4.8M | 344k | 14.05 | |
| Ocuphire Pharma (IRD) | 0.4 | $4.6M | 1.1M | 4.11 | |
| 4d Molecular Therapeutics In (FDMT) | 0.4 | $4.4M | 334k | 13.30 | |
| Intellia Therapeutics (NTLA) | 0.4 | $4.2M | 250k | 16.92 | |
| Voyager Therapeutics (VYGR) | 0.4 | $4.1M | 1.2M | 3.50 | |
| Biodesix (BDSX) | 0.4 | $4.1M | 180k | 22.55 | |
| Rocket Pharmaceuticals (RCKT) | 0.3 | $3.4M | 1.0M | 3.42 | |
| Jade Biosciences Com New (JBIO) | 0.3 | $3.2M | 145k | 22.22 | |
| Sanuwave Health (SNWV) | 0.3 | $3.1M | 306k | 10.00 | |
| Fortress Biotech Com New (FBIO) | 0.2 | $2.7M | 890k | 3.06 | |
| Journey Med Corp (DERM) | 0.2 | $2.5M | 350k | 7.08 | |
| Phathom Pharmaceuticals (PHAT) | 0.2 | $2.0M | 186k | 10.85 | |
| Inhibrx Biosciences (INBX) | 0.2 | $1.9M | 20k | 94.75 | |
| Enanta Pharmaceuticals (ENTA) | 0.2 | $1.8M | 125k | 14.58 | |
| Hemab Therapeutics Hldgs Com Shs | 0.2 | $1.8M | 48k | 36.73 | |
| First Tracks Biotherapeutics Ord Shs (TRAX) | 0.1 | $1.3M | 65k | 20.12 | |
| Cg Oncology (CGON) | 0.1 | $1.3M | 18k | 71.05 | |
| Biohaven (BHVN) | 0.1 | $1.2M | 78k | 14.88 | |
| Atea Pharmaceuticals (AVIR) | 0.1 | $1.1M | 235k | 4.65 | |
| Pasithea Therapeutics Corp Com New (KTTA) | 0.1 | $1.1M | 2.1M | 0.52 | |
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $749k | 700k | 1.07 | |
| Okyo Pharma Shs New (OKYO) | 0.1 | $563k | 375k | 1.50 | |
| Palatin Technologies Com New (PTN) | 0.0 | $221k | 21k | 10.79 | |
| Adagio Med Hldgs (ADGM) | 0.0 | $13k | 18k | 0.72 |
